Finanzen von China SXT Pharmaceuticals Inc (SXTC)SXTCChina SXT Pharmaceuticals Inc

China SXT Pharmaceuticals Inc (SXTC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Regular TCMP, accounting for 107.1% of total sales, equivalent to $547.84K. Other significant revenue streams include Others and Advanced TCMP. Understanding this composition is critical for investors evaluating how SXTC navigates market cycles within the Pharmaceuticals industry.

In the context of the broader market, SXTC competes directly with industry leaders such as BDRX and SPRC. With a market capitalization of $424.66K, it holds a significant position in the sector. When comparing efficiency, SXTC's gross margin of N/A stands against BDRX's N/A and SPRC's N/A. Such benchmarking helps identify whether China SXT Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows troubling signs, with a forward P/E of 0 and a price-to-sales ratio of 0.437, suggesting low valuation relative to sales but also highlighting the company's struggles to generate profit.